Device implantation in patients receiving non-vitamin K oral anticoagulants: consensus recommendations
| Non-vitamin K oral anticoagulants should probably be temporarily discontinued for all device surgery. |
| The period of discontinuation should be based on product characteristics. |
| It is suggested that the first dose of NAOC should be ≥24–48 h after surgery. The timing of the resumption should be based on individual assessment of the competing risks of stroke risk and pocket haematoma. |
| Non-vitamin K oral anticoagulants should probably be temporarily discontinued for all device surgery. |
| The period of discontinuation should be based on product characteristics. |
| It is suggested that the first dose of NAOC should be ≥24–48 h after surgery. The timing of the resumption should be based on individual assessment of the competing risks of stroke risk and pocket haematoma. |
Device implantation in patients receiving non-vitamin K oral anticoagulants: consensus recommendations
| Non-vitamin K oral anticoagulants should probably be temporarily discontinued for all device surgery. |
| The period of discontinuation should be based on product characteristics. |
| It is suggested that the first dose of NAOC should be ≥24–48 h after surgery. The timing of the resumption should be based on individual assessment of the competing risks of stroke risk and pocket haematoma. |
| Non-vitamin K oral anticoagulants should probably be temporarily discontinued for all device surgery. |
| The period of discontinuation should be based on product characteristics. |
| It is suggested that the first dose of NAOC should be ≥24–48 h after surgery. The timing of the resumption should be based on individual assessment of the competing risks of stroke risk and pocket haematoma. |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
